Professor, Medicine, Pennsylvania State University College of Medicine
Oncology
Dr. David F. Claxton, MD
|
|
Give Review
David F. Claxton practices Oncology. He received awards:"America's Top Doctors" and "America's Top Doctors for Cancer". Doctor David F. Claxton, MD is a published physician. He published 86 publications, including: 'Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.' David F. Claxton accepts Medicare payments and is listed with Medicare.gov.
Publications
- Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in Acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics.
- Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological Cancer cells.
- Maritoclax induces apoptosis in Acute myeloid leukemia cells with elevated Mcl-1 expression.
- G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete enGraftment after allogeneic hematopoietic transplantation.
- Emerging molecular therapies for the treatment of Acute lymphoblastic leukemia.
- Tyrosine kinase targeted treatment of chronic myelogenous Leukemia and other myeloproliferative neoplasms.
- Oral sapacitabine for the treatment of Acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
- Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of Cancer.
- Targeted Indocyanine-Green-Loaded Calcium Phosphosilicate Nanoparticles for In Vivo Photodynamic Therapy of Leukemia.
- Out foxing bcr-abl.
- A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.
- SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies.
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic Leukemia.
- Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in Acute myeloid leukemia with inv(16)(p13q22).
- A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia.
- Cellular composition of rat bone marrow stroma. Antigen-defined subpopulations.
- Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation.
- Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
- Autologous immunotherapy for human Leukemias.
- Response to bortezomib in refractory type I cryoglobulinemia.
- Tacrolimus does not abrogate the increased risk of Acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 an...
- T-cell blast crisis of chronic myelogenous Leukemia manifesting as a large mediastinal tumor.
- High-dose chemotherapy for relapsed and refractory diffuse large B-cell Lymphoma: mediastinal localization predicts for a favorable outcome.
- Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant Lymphoma.
- Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous Leukemia patients and f...
- Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and Acute myelogenous leukemia.
- Genetic therapy of human neoplastic Disease.
- Development of a sensitive PCR to detect allele loss in a model hematopoietic neoplasm.
- Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of Leukemia relapse following a prior transplant: results of a phase I study.
- Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities.
- Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
- Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous Cells to recovery after preparative therapy. The University of Te...
- Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit Cells do not contribute to posttransplant hematopoietic recovery fo...
- Tacrolimus and minidose methotrexate for prevention of Acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
- Allogeneic peripheral blood stem Cell transplantation using normal patient-related pediatric donors.
- CD2 expression and the PML-RAR gene.
- Acanthamoeba meningoencephalitis after bone marrow transplantation.
- Prognostic factors for Disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin''s l...
- Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
- Risk factors for Acute graft-versus-host disease after allogeneic blood stem cell transplantation.
- Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous Leukemia.
- Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated Acute myelogenous leukemia.
- Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-Leukemia without myeloablative therapy.
- Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome.
- Molecular analysis of retroviral transduction in chronic myelogenous Leukemia.
- Melphalan and purine Analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor...
- Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
- Transplant-lite: induction of Graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatmen...
- Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in Acute myelogenous leukemia.
- Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid Leukemia cells.
- High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in Acute myelogenous leukemia.
- Phase II study of clofarabine monotherapy in previously untreated older adults with Acute myeloid leukemia and unfavorable prognostic factors.
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell Lymphoma.
- Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast Cancer.
- Potential for therapy with AML-derived dendritic Cells.
- Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous Leukemia depends on percentage...
- Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous Leukemia (CML) contribute to relapse after autologous bone marrow in CML.
- Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous Leukemia.
- The gene product of CBFB-MYH11.
- Human Leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.
- CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in Myeloid and lymphoid cells.
- Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous Leukemia.
- Molecular genetics of inversion 16 Leukemia: implications for leukemogenesis.
- Acute leukemias: phenotyping and genotyping.
- The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
- Expression of unusual immunophenotype combinations in Acute myelogenous leukemia.
- Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in Acute myeloid leukemia.
- Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with Acute myelomonocytic leukemia.
- Smooth muscle myosin heavy chain locus (MYH11) maps to 16p13.13-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16.
- Detection of fusion transcripts generated by the inversion 16 chromosome in Acute myelogenous leukemia.
- Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis.
- Correlation of CD2 expression with PML gene breakpoints in patients with Acute promyelocytic leukemia.
- Retinoids and Cancer therapy.
- Apoptosis. Molecules and mechanisms.
- Dendritic cells derived in vitro from Acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.
- PML/RARalpha, a fusion protein in Acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
- Molecular anatomy of chromosome 7q deletions in Myeloid neoplasms: evidence for multiple critical loci.
- Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast Cancer.
- BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
- Sirolimus in unmanipulated haploidentical Cell transplantation.
- Therapeutic potential of Leukemia-derived dendritic cells: preclinical and clinical progress.
- Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated Leukemia cells in human blood.
- Control of advanced and refractory Acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
- Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin Lymphomas and are attractive targets for novel pharmacological interventions.
- Oral administration of Analgesia and anxiolysis for pain associated with bone marrow biopsy.
Schools
McGill University Faculty of Medicine
Royal Jubilee Hospital
Royal Victoria Hospital
UTMD Anderson Cancer Center
Procedures Preformed
- Bone Marrow Transplant
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- View All
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Texas Health Science Center -
McGill University Faculty of Medicine
Hospital
-
Penn State Milton S. Hershey Medical Center
Drug Facts
| NPI NUMBER | 1073562351 | |
| NPPES Provider LastName | CLAXTON | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 170332360 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 885.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 52.0 | |
| Percent Opioid Claims | 5.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073562351 |
| Last Name Of The Provider | CLAXTON |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Amit Barochia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc A. Rovito, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William A. Flood Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheldon Holder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cristina I. Truica, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward J. Gunther, MD
This Doctor is OpenDoctor Recommended.
|